stones (less efficient).We view this diversification into urology asth Video Urology world congress

Energy delivery system.

Stonebreaker is the method which the device is able to transfer energy to

the tip of the probe which will be in contact with the stone. The kinetic

energy delivered to the stone then utilises the natural faults in the stone to

fragment it into manageable sized fragments for removal. There is minimal

probe movement thus reducing stone movement away from the probe

(retropulsion).The key Intellectual Property (IP) behind the

1

come from the sales of the device. With an average sale price of US$7500,

it comes much more affordable than other lithotripsy machines. Capital

good purchases typically have a threshold below US$10,000 so hospitals

or small urology centres will be able to easily get their hands on the

Stonebreaker without much paperwork. The Swiss Lithoclast has an

estimated installed base of about 5000 worldwide and we expect LMA to

be aggressive in taking its market share and to promote this in the Asian

region due to its portability and lower price point.st phase revenue stream. The Stonebreaker?s 1st phase of revenue will

Page 12 30 March 2007

LMA International NV

2

expect to see higher usage and thus an increase in revenue of the

consumable probes and CO2 cartridges. Management has highlighted that

these consumables are difficult to replicate for the Stonebreaker to deliver

the same performance. We note that the likelihood of re-use of probes is

more probable than buying cheaper 3

has mentioned that new flexible probes are being designed as an additional

offering to the present straight probe.nd phase revenue stream. With an increase in the installed base, werd party consumables. Management

Endorsement of product.

LMA has signed an exclusive distributorship agreement with EDAP. EDAP,

with more than 25 years of experience in sales and distribution, has a

strong knowledge of the medical community in France. The company has

significant expertise in the domestic lithotripsy market and a dedicated

distribution network.As a show of quick marketing execution footwork,

Current Stonebreaker capacity.

are able to produce Stonebreakers by the ?hundreds? from their Switzerland

plant but it would be simple to replicate the production line and thus

quadrupling capacity if necessary.Management has indicated that they

Forecast for Urology.

for the Urology segment. As guided, we forecast that the Stonebreaker will

grow exponentially from its small base to contribute about US$3m in FY07

and grow 120% YoY to contribute US$6.5m in FY08.Management is confident of achieving strong growth

stones range in consistency (soft to hard) and size (speck-sized to walnutsized).LMA has opted to enter the urology market by

?Stone hard? facts:

- 12% of Americans will have a kidney stone some time in their life

- Prevalence of urolithiasis in the American population is 5.2% (up

from 3.8% from 30 years ago)

- In 2000, 600k Americans went to the emergency room for stone

related pain

- 1/3 of all visits to a urologists are for kidney stones

- The development of the stones is related to decreased urine volume

or increased excretion of stone-forming components such as

calcium, oxalate, urate, cystine, xanthine, and phosphate. It is

expected to be increasingly prevalent.

Emerging markets are calling.

Pacific HQ in Singapore is due to the proximity of major emerging markets

of China (2.1b people) and India (1.1b people). Stone burden is large and

complex systems are costly and are only available at large hospitals,

rendering the majority of the rural population without an adequate solution.

The Stonebreaker will give urologists a compact, portable and self powered

device to address this huge rural need.

FOR IMMEDIATE RELEASE

LMA receives FDA approval to market urology device LMA StoneBreakerTM

in the US

Singapore, 17 May 2007

development and marketing of the LMA

management devices, announced today that the Food and Drug Administration (?FDA?) has granted

approval for LMA to commence marketing the LMA StoneBreaker

The revolutionary and innovative system, manufactured in Switzerland, received the CE mark in June

2006. The effectiveness of this kinetic intracorporeal lithotripsy technique has been proven by a

peer-reviewed clinical trial and several hundred clinical cases to date. Sales of the device have

already commenced in Europe and Asia.

LMA Group President and CEO Michael Ashton said, ?We are extremely pleased with this latest

development. Based on the positive response and increasing demand for the device in other parts of

the world since its introduction last year, we anticipate demand from the US to fuel sales growth in

the second half of FY2007.?

The LMA StoneBreaker

stones in the urinary tract. This handheld system complements lithotripsy procedures performed with

extra-corporeal shockwave lithotripsy devices by targeting kidney stones located in places which